Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33results about How to "Improve absorption and bioavailability" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Compositions for oral drug administration
InactiveUS20140162965A1Promote absorptionImprove bioavailabilityBiocideCarbohydrate active ingredientsGlycosideOral medication
The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.
Owner:AEGIS THERAPEUTICS LLC
Absorption Enhancers for Drug Administration
ActiveUS20080299079A1Improve absorption and bioavailabilityToxic effectsBiocideNervous disorderActive agentPancreatic hormone
A composition including a surfactant and at least one alkyl glycoside and / or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
Owner:AEGIS THERAPEUTICS LLC
Absorption enhancers for drug administration
InactiveUS20060045869A1Avoid effectIncrease absorption and bioavailability of drugBiocideNervous disorderDrugDrug administration
A composition including a surfactant and at least one alkyl glycoside and / or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
Owner:AEGIS THERAPEUTICS LLC +1
Absorption enhancers for drug administration
InactiveUS20060046962A1Improve absorption and bioavailabilityHigh bioavailabilitiesBiocideNervous disorderDrugDrug administration
A composition including a surfactant and at least one alkyl glycoside and / or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
Owner:UAB RES FOUND +1
Absorption enhancers for drug administration
InactiveUS20060045868A1Improve absorption and bioavailabilityToxic effectsPowder deliveryBiocideInhalationDrug administration
A composition including a surfactant and at least one alkyl glycoside and / or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
Owner:AEGIS THERAPEUTICS LLC +1
Compositions for Drug Administration
InactiveUS20090047347A1Improve absorption and bioavailabilityToxic effectsPowder deliveryBiocideDrug metabolismHepatic first pass effect
The present invention provides compositions and methods and for speeding the onset of drug action and reducing the first-pass effect drug metabolism in fast-dispersing drug formulations.
Owner:AEGIS THERAPEUTICS LLC
Compositions for Drug Administration
ActiveUS20090163447A1Promote absorptionImprove bioavailabilityBiocideNervous disorderMedicineChain length
The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Owner:AEGIS THERAPEUTICS LLC
Antibacterial compositions for drug administration
InactiveUS20060046969A1Avoid effectIncrease absorption and bioavailability of drugBiocidePeptide/protein ingredientsDrugDrug administration
An antibacterial composition having at least one alkyl glycoside, at least one saccharide, and at least one therapeutic agent, wherein the alkyl glycoside has an alkyl chain length from about 12 to about 14 carbon atoms and wherein the saccharide has antibacterial activity, thereby providing for a composition having antibacterial activity.
Owner:AEGIS THERAPEUTICS LLC
Compositions for drug administration
ActiveUS20100160378A1Improve absorption and bioavailabilityToxic effectsBiocideNervous disorderChain length5-HT receptor
The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Owner:AEGIS THERAPEUTICS LLC
Gastric Retention and Controlled Release Delivery System
InactiveUS20080153779A1Improve absorption and bioavailabilityBetter absorbed in the stomachOrganic active ingredientsPharmaceutical delivery mechanismControlled releaseElectrical conductor
The present invention provice a device (FIG. 3) for providing communication through power lines (FIG. 2) comprised of multiple conductors by transmitting the data signals through a plurality of the conductors. One embodiment of the present invention comprises a transmit circuit communicatively coupled to a first conductor for applying the first voltage representing the data to the first energized conductor; the transmit circuit communicatively coupled to a second conductor for applying the second voltage representing the data to the second energized conductor; wherein the second voltage signal is opposite in polarity of the first voltage.
Owner:NOVO NORDISK NORTH AMERICA OPERATIONS AS
Compositions for drug administration
InactiveUS20110257096A1Promote absorptionImprove bioavailabilityPeptide/protein ingredientsSomatostatinsChain lengthDrug administration
The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery of peptides containing non-naturally occurring structures including D-amino acids and / or chain cyclization.
Owner:AEGIS THERAPEUTICS LLC
Alkylglycoside compositions for drug administration
ActiveUS8268791B2Improve absorption and bioavailabilityToxic effectsBiocideNervous disorderGlycosideDrug administration
Owner:AEGIS THERAPEUTICS LLC
Antibacterial compositions for drug administration
ActiveUS20100068209A1Promote absorptionImprove bioavailabilityBiocidePharmaceutical delivery mechanismMicroorganismGlycoside formation
Non-toxic aqueous compositions are provided having antibacterial activity. Specifically, the invention provides aqueous alkyl glycoside or saccharide alkyl ester compositions which meet the antimicrobial effectiveness test criteria set forth in USP 31 <51> in preventing growth of specified bacteria and fungi.
Owner:AEGIS THERAPEUTICS LLC
Antiviral activity possessed compound and preparation method thereof
ActiveCN1566118AGood stabilityImprove absorption and bioavailabilityDigestive systemAntiviralsWater solubleStereochemistry
The invention discloses a novel compound having a general formula discloses in the specification, a process for preparing the compound, and novel intermediate compound related in the compound synthesizing flow path. The compound provided by the invention can be used for preparing multiple pharmaceutical preparations for treating a plurality of diseases caused by virus infection.
Owner:CHENGDU DIAO JIUHONG PHARMA FACTORY
Immunoactive Compositions for Improved Oral Delivery of Vaccines and Therapeutic Agents
InactiveUS20080226682A1Raise the ratioImprove absorption and bioavailabilitySsRNA viruses negative-senseBiocideEnzyme Inhibitor AgentIsoflavones
The present invention concerns methods and compositions for improved oral delivery of bioactive agents, such as vaccines. In preferred embodiments, the compositions comprise at least one lectin, saponin, polyunsaturated fatty acid and / or isoflavone. In further embodiments, the compositions may further comprise at least one protease inhibitor, buffer and / or surfactant. In more preferred embodiments, the lectins, saponins, fatty acids, isoflavones and / or protease inhibitors may be derived from extracts, homogenates, finely ground powders or derivatives of plant or animal material, such as beans, nuts, peas, fish meal or krill. The relative amounts of various naturally occurring materials contained in the compositions may be selected to optimize the concentrations of one or more lectins, saponins, polyunsaturated fatty acids and / or isoflavones. The compositions are of use for oral delivery of a wide variety of bioactive agents, particularly protein or peptide based agents.
Owner:PEROS SYST TECH
Compositions for drug administration
ActiveUS20080200418A1Improve absorption and bioavailabilityToxic effectsPharmaceutical delivery mechanismCarbohydrate active ingredientsGlycosideChain length
A composition having at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms and wherein the therapeutic agent is an oligonucleotide.
Owner:AEGIS THERAPEUTICS LLC
Compositions for drug administration
ActiveUS20140107145A1Improve absorption and bioavailabilityToxic effectsBiocidePharmaceutical delivery mechanismChain lengthBioavailability
The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Owner:INDIVIOR UK +1
Compositions for drug administration
ActiveUS9895444B2Improve absorption and bioavailabilityToxic effectsOrganic active ingredientsPharmaceutical delivery mechanismChain lengthDrug administration
The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Owner:INDIVIOR UK +1
Orally dispersible multi-micronutrient dietary supplement composition and methods of using same
InactiveUS20130323350A1Acceptable mouth feelGood for healthMilk preparationVitamin food ingredientsDietary supplementBioavailability
The present invention is directed to a novel orally dispersible multi-micronutrient dietary supplement in a tablet dosage form. Use of lipid encapsulated substrates, flavorings, sweeteners and bitter masking agents provides for a dosage that suppresses unpleasant tastes or aftertastes and imparts a pleasant mouth feel when the tablet disperses after being sucked or chewed for several minutes. The combination of lipid encapsulated substrates, oral disintegration and multiple daily dosing schedule provides for improved bioavailability of several crucial micronutrients.
Owner:SELIGSON ALLEN
Compositions for drug administration
InactiveUS20120021980A1Improve absorption and bioavailabilityToxic effectsPeptide/protein ingredientsMetabolism disorderChain lengthDrug administration
The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery of glucagon-like peptide-1 analogs, such as exenatide, albiglutide, taspoglutide, liraglutide and lixisenatide.
Owner:AEGIS THERAPEUTICS LLC
Compositions for oral drug administration
ActiveUS20180104344A1Improve absorption and bioavailabilityToxic effectsCarbohydrate active ingredientsPharmaceutical non-active ingredientsGlycosideChain length
Owner:AEGIS THERAPEUTICS LLC
Absorption enhancers for drug administration
ActiveUS20120196941A1Improve absorption and bioavailabilityToxic effectsBiocideNervous disorderIrritationInhalation
A composition including a surfactant and at least one alkyl glycoside and / or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
Owner:AEGIS THERAPEUTICS LLC
Compositions for drug administration
ActiveUS8642564B2Improve absorption and bioavailabilityToxic effectsBiocideGenetic material ingredientsGlycosideChain length
Owner:AEGIS THERAPEUTICS LLC
Compositions for drug administration
InactiveUS20180000942A1Promote absorptionImprove bioavailabilityOrganic active ingredientsInorganic non-active ingredientsChain lengthBioavailability
The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Owner:AEGIS THERAPEUTICS LLC
Compositions for drug administration
ActiveUS8440631B2Improve absorption and bioavailabilityToxic effectsBiocideNervous disorder5-HT receptorChain length
Owner:AEGIS THERAPEUTICS LLC
Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
InactiveUS6908900B2Promote absorptionImprove bioavailabilityNervous disorderPeptide/protein ingredientsOral medicationParenteral nutrition
Disclosed herein are novel pharmaceutical agents and compositions, as well as novel methods, to enhance the absorption of polypeptide drug substances that normally display little if any absorbability if administered orally. Also disclosed are novel compositions and methods to significantly enhance the bioavailability and pharmacological efficacy of polypeptide drug substances whether administered orally or parenterally.
Owner:IMMPHARMA SA +1
Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
InactiveUS7671029B2Improve absorption and bioavailabilitySlow kineticsPeptide/protein ingredientsAntipyreticPeptide drugMethylenedioxy
Pharmaceutical agents, compositions containing the same and methods for their use for enhancing the bioavailability and pharmacological efficacy of therapeutic peptides. The pharmaceutical agents have the formulaCarrier-Linker-PeptideWherein Peptide is a therapeutically active peptide species having the formula aan wherein n is the number of amino acid residues in the peptide and n is 2 to 40, Carrier is benzoyl, phenylacetyl, cinnamoyl, 3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3,4-dimethoxycinnamoyl, 3,4-methylenedioxycinnamoyl, 3-methoxycinnamoyl, 3,4-diethoxy-cinnamoyl, 3,4,5-trimethoxy-cinnamoyl, t-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylmethoxycarbonyl, fumaroyl and derivatives thereof and Linker is a C6 to C16 lipidic chain or a derivative thereof, an 8-amino-3,6-dioxaoctanoic acid or polymeric derivative thereof, pseudo peptide, or peptide mimic. Methods of use of compositions having the formula Carrier-Peptide wherein Carrier and Peptide are as just defined are also disclosed.
Owner:UREKA
Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and method of manufacturing the same
InactiveUS20140057860A1Good absorbing effectInhibit MRPBiocideCarbohydrate active ingredientsDrugOral medication
The present invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and the method of preparation thereof. The aforesaid pharmaceutical composition is prepared by the following components in weight percent: 0.1%-0.3% scutellarin, 20%-25% co-surfactant, 40-50% surfactant, and 25-30% oil. The method of preparing the aforesaid pharmaceutical composition comprises the steps of: (1) dispersing scutellarin in co-surfactant and surfactant to obtain a mixture; (2) dispersing the mixture from step (1) in oil, and thermostatically and magnetically stirring the dispersion mixture under the temperature of 25° C. to 37° C., such that the components thereof are completely dissolved to obtain the pharmaceutical composition. Through the use of the selected pharmaceutical adjuvants having the ability to inhibit MRP2, the aforesaid pharmaceutical composition effectively improves absorption and bioavailability of scutellarin. The preparation of the aforesaid pharmaceutical composition is simple and convenient, and the pharmaceutical composition can be processed into a variety of dosage forms for oral administration.
Owner:MACAU UNIV OF SCI & TECH
Compositions and Methods for Enhanced Pharmacological Activity of Compositions Comprising Peptide Drug Substances
InactiveUS20100292158A1Improve absorption and bioavailabilitySlow kineticsDipeptide ingredientsAntipyreticPeptide drugMethylenedioxy
Pharmaceutical agents, compositions containing the same and methods for their use for enhancing the bioavailability and pharmacological efficacy of therapeutic peptides. The pharmaceutical agents have the formulaCarrier-Linker-PeptideWherein Peptide is a therapeutically active peptide species having the formula aan wherein n is the number of amino acid residues in the peptide and n is 2 to 40, Carrier is benzoyl, phenylacetyl, cinnamoyl, 3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3,4-dimethoxycinnamoyl, 3,4-methylenedioxycinnamoyl, 3-methoxycinnamoyl, 3,4-diethoxy-cinnamoyl, 3,4,5-trimethoxy-cinnamoyl, t-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylmethoxycarbonyl, fumaroyl and derivatives thereof and Linker is a C6 to C16 lipidic chain or a derivative thereof, an 8-amino-3,6-dioxaoctanoic acid or polymeric derivative thereof, pseudo peptide, or peptide mimic. Methods of use of compositions having the formula Carrier-Peptide wherein Carrier and Peptide are as just defined are also disclosed.
Owner:UREKA
Composition for treating worms infestations
ActiveUS20200222440A1Promote absorptionImprove bioavailabilityOrganic active ingredientsPharmaceutical delivery mechanismBioresorbable polymersMacrocyclic lactone
The present invention relates to an injectable implant comprising an effective amount of a macrocyclic lactone, or a salt thereof, and a bioresorbable polymer, and its use in preventing and / or treating parasites infestations in non human mammals, especially pets.
Owner:CEVA SANTE ANIMALE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com